LifeMD, Inc.
LifeMD, Inc. operates as a leading digital health company, specializing in direct-to-consumer telemedicine across the United States. The firm links individuals with licensed medical professionals to address a diverse spectrum of health concerns, including concierge services, men's sexual health, dermatological…
1D
-4.9%
1W
-11.0%
1M
-27.1%
6M
-42.8%
YTD
-31.4%
1Y
-63.6%
2Y
-50.8%
5Y
-54.8%
10Y
+73.3%
Next earnings date
11/11/2026 (in 25 days)
Volatility around earnings
~13% weaker price swings than usual
PRICE TARGET LOW
US$5.00
CONSENSUS
US$7.00
MEDIAN
US$7.00
PRICE TARGET HIGH
US$9.00
0
STRONG BUY
10
BUY
0
HOLD
0
SELL
0
STRONG SELL
10
TOTAL · Buy
As of: 17/09/2026
P/E
-4.61
P/B
14.04
EV/EBITDA
-8.39
RETURN ON EQUITY
-88.9%
NET MARGIN
-15.0%
DEBT/EQUITY
0.76
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
82.2%
FLOAT SHARES
39,655,793
AVG. DAILY VOLUME (30D)
813,260
Strawn John R Jr
LAROVERE JOAN
Strawn John R Jr
DiTrolio Joseph
Simon Roberto
LifeMD, Inc. is a company in the Healthcare sector, Medical - Healthcare Information Services industry, headquartered in United States.
The CEO is Justin Schreiber, the company employs around 350 people.
The IPO was on 29/01/2008; the stock trades on NASDAQ under the ticker LFMD.
10 analysts rate the stock, the consensus is Buy (as of 17/09/2026).
The average price target is US$7.00, ranging from US$5.00 to US$9.00, with a median of US$7.00.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 11/11/2026.
Around past earnings, price swings were roughly -13% stronger than usual.
No, LifeMD currently does not pay a dividend.
Comparable stocks include Hinge Health, HealthEquity, Heartflow, Omada Health, Teladoc Health, Evolent Health, SOPHiA GENETICS and Optima Health.
Clicking "Analyze stock" lets five strategies assess LifeMD against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.